Community Empowerment Through Family Medicinal Plants (TOGA)
DOI:
https://doi.org/10.59247/jppmi.v2i7.115Keywords:
TOGA, immune enhancing herbs, community empowermentAbstract
Since the outbreak of Covid-19, the popularity of medicinal plants has increased. Strong immunity is believed to prevent yourself from being exposed to the virus outbreak. The community believes that using traditional medicines such as herbal medicine from ginger, turmeric, ginger or kencur can increase the body's immunity. Family medicinal plants (TOGA) are family (home) cultivated plants that have medicinal properties. TOGA planting can be done in pots or on the land around the house, and if the land planted is large enough then some of the crops can be sold and increase family income. Banjarharjo 1 is one of the hamlets in Muntuk Village, Dlingo District, Bantul Regency. Geographically, Muntuk Village is a village located in an area that is in the highlands. Communities in the village area generally still have a large yard of land. The results of field observations show that the current development of TOGA is more on the aspect of cultivation only with utilization that is not optimal and limited to oneself and one's family. Communities who already have knowledge about the efficacy of TOGA and master how to process it can cultivate medicinal plants individually and use them so that the principle of independence in family medicine will be realized. Especially during the Covid-19 pandemic, processing herbal medicine to maintain health with ingredients derived from their own plants will really help maintain economic stability as well. Based on an analysis of the problems faced by partners, several efforts can be made as a solution to empower the people of Banjarharjo 1 Village in increasing the use of TOGA in the Making of Herbal Medicine to Increase Body Immunity as a Prevention of Covid-19. This PKM activity was carried out using the method of observation, counseling, mentoring and demonstration of making herbal medicine from the TOGA plant. The application of technology begins with training partners in terms of introducing TOGA types, cultivation and planting methods, as well as processing/manufacturing TOGA products for CPOTB-based family medicines and herbs. In addition, training was also made on making good and attractive packaging. The partners of the Banjarharjo Village 1 PKK team who collaborated with the proposer provided active participation in the provision of existing places and facilities. The results of the activity showed that residents already had knowledge about how to plant TOGA, knew about the benefits of TOGA for maintaining health, as well as raised awareness among residents to grow medicinal plants around their homes and increased skills in processing herbal medicine from TOGA.
References
E. James et al., “Characteristics, treatment outcomes and experiences of COVID-19 patients under home-based care in Kapelebyong district in Uganda: a mixed-methods study,” Trop. Med. Health, vol. 50, no. 1, p. 93, Dec. 2022.
N. Sahay, D. K. Rai, and P. Lohani, “Clinical Characteristics and Treatment Outcomes of 293 COVID-19 Patients Admitted to the Intensive Care Unit of a Tertiary Care Hospital of Eastern India,” Indian J. Crit. Care Med., vol. 25, no. 12, pp. 1395–1401, Dec. 2021.
C. Liu et al., “Clinical features and multidisciplinary treatment outcome of COVID-19 pneumonia: A report of three cases,” J. Formos. Med. Assoc., vol. 119, no. 11, pp. 1702–1709, Nov. 2020.
Z. Li et al., “A five-year review of prevalence and treatment outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis in the Henan Provincial Tuberculosis Clinical Medicine Research Centre,” J. Glob. Antimicrob. Resist., vol. 31, pp. 328–336, Dec. 2022.
D. L. Ramatillah et al., “Evaluation of Treatment Outcome for Pneumonia among Pre-Vaccinated COVID-19 Patients with/without Comorbidity in a Public Hospital in Bengkulu, Indonesia,” Vaccines, vol. 9, no. 12, p. 1411, Nov. 2021.
R. M. Deacon et al., “Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations,” Drug Alcohol Rev., vol. 39, no. 5, pp. 441–446, Jul. 2020.
M. Reeson et al., “Child sexual abuse survivors: Differential complex multimodal treatment outcomes for pre-COVID and COVID era cohorts,” Child Abuse Negl., vol. 134, p. 105926, Dec. 2022.
R. Sirijatuphat et al., “Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand’s university-based referral hospital,” BMC Infect. Dis., vol. 21, no. 1, p. 382, Dec. 2021.
H. Pan et al., “Treatment outcomes and prognostic factors for non- malignancy associated secondary hemophagocytic lymphohistiocytosis in children,” BMC Pediatr., vol. 20, no. 1, p. 288, Dec. 2020.
C. M. Laffont et al., “Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder,” Front. Pharmacol., vol. 13, Nov. 2022.
S. Peng et al., “The role of chest CT quantitative pulmonary inflammatory index in the evaluation of the course and treatment outcome of COVID-19 pneumonia,” Sci. Rep., vol. 11, no. 1, p. 7752, Apr. 2021.
A. Allegra, G. Pioggia, A. Tonacci, C. Musolino, and S. Gangemi, “Cancer and SARS-CoV-2 Infection: Diagnostic and Therapeutic Challenges,” Cancers (Basel)., vol. 12, no. 6, p. 1581, Jun. 2020.
K. Krpina, M. Mavrinac, M. Samarzija, E. Tolic, D. Darapi, and L. Baticic, “Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection,” J. Clin. Med., vol. 11, no. 22, p. 6695, Nov. 2022.
K.-W. Kang et al., “The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma,” Korean J. Intern. Med., vol. 36, no. 6, pp. 1459–1470, Nov. 2021.
L. Zou, L. Dai, X. Zhang, Z. Zhang, and Z. Zhang, “Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19,” Arch. Pharm. Res., vol. 43, no. 8, pp. 765–772, Aug. 2020.
H. V. Masina, I.-F. Lin, and L.-Y. Chien, “The Impact of the COVID-19 Pandemic on Tuberculosis Case Notification and Treatment Outcomes in Eswatini,” Int. J. Public Health, vol. 67, Oct. 2022.
E. Gombert et al., “Treatment outcomes in patients with laryngotracheal lesions and compromised airway during and prior to the coronovirus disease 2019 pandemic: a tertiary institution’s experience,” J. Laryngol. Otol., vol. 135, no. 10, pp. 897–903, Oct. 2021.
S. D. Hajdu et al., “Acute Stroke Management During the COVID-19 Pandemic,” Stroke, vol. 51, no. 8, pp. 2593–2596, Aug. 2020.
Y. Yakupogullari et al., “Diagnostic and treatment outcomes of patients with pulmonary tuberculosis in the first year of COVID-19 pandemic,” East. Mediterr. Heal. J., vol. 28, no. 9, pp. 682–689, Sep. 2022.
S. Alghamdi, “Clinical characteristics and treatment outcomes of severe (ICU) COVID-19 patients in Saudi Arabia: A single centre study,” Saudi Pharm. J., vol. 29, no. 10, pp. 1096–1101, Oct. 2021.
S. Ganatra, S. P. Hammond, and A. Nohria, “The Novel Coronavirus Disease (COVID-19) Threat for Patients With Cardiovascular Disease and Cancer,” JACC CardioOncology, vol. 2, no. 2, pp. 350–355, Jun. 2020.
K. K. Sharma et al., “Randomised trial to determine the effect of vitamin D and zinc supplementation for improving treatment outcomes among patients with COVID-19 in India: trial protocol,” BMJ Open, vol. 12, no. 8, p. e061301, Aug. 2022.
S. Lakoh et al., “Impact of COVID-19 on Tuberculosis Case Detection and Treatment Outcomes in Sierra Leone,” Trop. Med. Infect. Dis., vol. 6, no. 3, p. 154, Aug. 2021.
O. Voisin et al., “Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection,” Mayo Clin. Proc., vol. 95, no. 8, pp. 1696–1700, Aug. 2020.
V. Vastis et al., “Impact of Protocol Adjustments Due to the COVID-19 Pandemic on Infertility Treatment Outcomes,” J. Obstet. Gynaecol. Canada, vol. 44, no. 9, pp. 1006–1010, Sep. 2022.
R. A. Martin et al., “Using implementation interventions and peer recovery support to improve opioid treatment outcomes in community supervision: Protocol,” J. Subst. Abuse Treat., vol. 128, p. 108364, Sep. 2021.
T. N. Nguyen, R. G. Nogueira, and T. G. Jovin, “Response by Nguyen et al to Letter Regarding Article, ‘Mechanical Thrombectomy in the Era of the COVID-19 Pandemic: Emergency Preparedness for Neuroscience Teams: A Guidance Statement From the Society of Vascular and Interventional Neurology,’” Stroke, vol. 51, no. 8, Aug. 2020.
T.-Y. Jang et al., “Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021,” J. Formos. Med. Assoc., vol. 121, no. 9, pp. 1767–1772, Sep. 2022.
N. Gharebaghi et al., “Evaluation of epidemiology, clinical features, prognosis, diagnosis and treatment outcomes of patients with COVID‐19 in West Azerbaijan Province,” Int. J. Clin. Pract., vol. 75, no. 6, Jun. 2021.
J. Liu, X. Zheng, Y. Huang, H. Shan, and J. Huang, “Successful use of methylprednisolone for treating severe COVID-19,” J. Allergy Clin. Immunol., vol. 146, no. 2, pp. 325–327, Aug. 2020.
T. B. Beressa et al., “Potential Benefits of Antiviral African Medicinal Plants in the Management of Viral Infections: Systematic Review,” Front. Pharmacol., vol. 12, Dec. 2021.
M. J. Choi and Y. R. Kim, “Anti-Allergic Effect of Fermented Extracts of Medicinal Plants Andrographis paniculate , Salvia plebeia R. Br., Canavalia gladiate , Eleuthorococcus senticosus , Ulmus davidiana var. japonica , and Clerodendrum trichotomum Thunb. ex Murray,” Microbiol. Biotechnol. Lett., vol. 50, no. 4, pp. 512–521, Dec. 2022.
N. A. ISHAK, M. HAMID, and N. A. Z, “ANTIDIABETIC PROPERTY OF MEDICINAL PLANTS IN MALAYSIA,” J. Sustain. Sci. Manag., vol. 16, no. 8, pp. 307–322, Dec. 2021.
P. Kanjanasirirat et al., “High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents,” Sci. Rep., vol. 10, no. 1, p. 19963, Nov. 2020.
S. Basnet et al., “In Vitro and In Silico Studies for the Identification of Potent Metabolites of Some High-Altitude Medicinal Plants from Nepal Inhibiting SARS-CoV-2 Spike Protein,” Molecules, vol. 27, no. 24, p. 8957, Dec. 2022.
T. P. Saliu, H. I. Umar, O. J. Ogunsile, M. O. Okpara, N. Yanaka, and O. O. Elekofehinti, “Molecular docking and pharmacokinetic studies of phytocompounds from Nigerian Medicinal Plants as promising inhibitory agents against SARS-CoV-2 methyltransferase (nsp16),” J. Genet. Eng. Biotechnol., vol. 19, no. 1, p. 172, Dec. 2021.
P. K. Parida, D. Paul, and D. Chakravorty, “The natural way forward: Molecular dynamics simulation analysis of phytochemicals from Indian medicinal plants as potential inhibitors of SARS‐CoV ‐2 targets,” Phyther. Res., vol. 34, no. 12, pp. 3420–3433, Dec. 2020.
E. Nyagumbo et al., “Medicinal plants used for the management of respiratory diseases in Zimbabwe: Review and perspectives potential management of COVID-19,” Phys. Chem. Earth, Parts A/B/C, vol. 128, p. 103232, Dec. 2022.
D. Khadka et al., “The use of medicinal plants to prevent COVID-19 in Nepal,” J. Ethnobiol. Ethnomed., vol. 17, no. 1, p. 26, Dec. 2021.
B. Benarba and A. Pandiella, “Medicinal Plants as Sources of Active Molecules Against COVID-19,” Front. Pharmacol., vol. 11, Aug. 2020.
S. Rathore, R. T. Tiwari, N. Rai, D. K. Mahapatra, S. Patil, and A. G. Patil, “A Review Article on the Therapeutic Potential of Medicinal Plants for Prevention and Treatment of Secondary Infection in Patients with COVID-19,” Curr. Tradit. Med., vol. 8, no. 6, Dec. 2022.
T. Dutta, N. Baildya, A. A. Khan, and N. N. Ghosh, “Inhibitory effect of anti-HIV compounds extracted from Indian medicinal plants to retard the replication and transcription process of SARS-CoV-2: an insight from molecular docking and MD-simulation studies,” Netw. Model. Anal. Heal. Informatics Bioinforma., vol. 10, no. 1, p. 32, Dec. 2021.
S. K. Devi, B. M. P., and A. S. S. Girija, “Structural Basis of SARS COV 2 3CL PRO Drug And AntiCOVID-19 Discovery from Medicinal Plants - A Review,” Int. J. Curr. Res. Rev., pp. 101–105, 2020.
J. Choe, P. Har Yong, and Z. Xiang Ng, “The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm,” Chem. Biodivers., vol. 19, no. 11, Nov. 2022.
O. O. Oyedara et al., “Computational screening of phytochemicals from three medicinal plants as inhibitors of transmembrane protease serine 2 implicated in SARS-CoV-2 infection,” Phytomedicine Plus, vol. 1, no. 4, p. 100135, Nov. 2021.
M. Divya, S. Vijayakumar, J. Chen, B. Vaseeharan, and E. F. Durán-Lara, “South Indian medicinal plants can combat deadly viruses along with COVID-19? - A review,” Microb. Pathog., vol. 148, p. 104277, Nov. 2020.
F. Yang et al., “Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19,” J. Integr. Med., vol. 20, no. 6, pp. 488–496, Nov. 2022.
B. K. Khuntia et al., “Ayurvedic Medicinal Plants Against COVID-19: An In Silico Analysis,” Nat. Prod. Commun., vol. 16, no. 11, p. 1934578X2110567, Nov. 2021.
C. Gao et al., “Characterization of Chloroplast Genomes From Two Salvia Medicinal Plants and Gene Transfer Among Their Mitochondrial and Chloroplast Genomes,” Front. Genet., vol. 11, Oct. 2020.
C. A. Odebunmi et al., “Ethnobotanical Survey of Medicinal Plants Used in the Treatment of COVID-19 and Related Respiratory Infections in Ogbomosho South and North Local Government Areas, Oyo State, Nigeria,” Plants, vol. 11, no. 19, p. 2667, Oct. 2022.
K. Malekmohammad and M. Rafieian-Kopaei, “Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),” Curr. Pharm. Des., vol. 27, no. 38, pp. 3996–4007, Oct. 2021.
V. K S, Abilasha, and K. S, “Knowledge About the Effects of Medicinal Plants Against COVID-19 Among Dental Students - A Questionnaire Study,” Int. J. Curr. Res. Rev., vol. 12, no. 19, pp. 97–108, 2020.
S. Chtita et al., “In silico investigation of phytoconstituents from Cameroonian medicinal plants towards COVID-19 treatment,” Struct. Chem., vol. 33, no. 5, pp. 1799–1813, Oct. 2022.
J. Julsrigival, P. Sirisa-ard, S. Julsrigival, and N. Akarchariya, “Antiviral medicinal plants found in Lanna traditional medicine,” Chinese Herb. Med., vol. 13, no. 4, pp. 494–501, Oct. 2021.
P. Parikh et al., “Prophylactic potential of Indian medicinal plants in the management of influenza like illness especially COVID-19,” Med. Plants - Int. J. Phytomedicines Relat. Ind., vol. 12, no. 3, p. 323, 2020.
L. Cordoba-Tovar et al., “Cultural belief and medicinal plants in treating COVID 19 patients of Western Colombia,” Acta Ecol. Sin., vol. 42, no. 5, pp. 476–484, Oct. 2022.
J. Yue, W. Li, and Y. Wang, “Superiority Verification of Deep Learning in the Identification of Medicinal Plants: Taking Paris polyphylla var. yunnanensis as an Example,” Front. Plant Sci., vol. 12, Sep. 2021.
J. O. Oladele et al., “A systematic review on COVID-19 pandemic with special emphasis on curative potentials of Nigeria based medicinal plants,” Heliyon, vol. 6, no. 9, p. e04897, Sep. 2020.
C. Zinga et al., “Use of Medicinal Plants in Africa: A Case Study From the Democratic Republic of Congo (DRC),” Semin. Nephrol., vol. 42, no. 5, p. 151319, Sep. 2022.
M. A. Alamri, A. Altharawi, A. B. Alabbas, M. A. Alossaimi, and S. M. Alqahtani, “Structure-based virtual screening and molecular dynamics of phytochemicals derived from Saudi medicinal plants to identify potential COVID-19 therapeutics,” Arab. J. Chem., vol. 13, no. 9, pp. 7224–7234, Sep. 2020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Iswanto Suwarno, Mi Jeong Choi , Keerththana Kumareswaran , Dawn Ching Tung Au , Jacqueline Aparecida Takahashi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
